VanEck Pharmaceutical ETF (NASDAQ:PPH) Hits New 12-Month High – Should You Buy?

VanEck Pharmaceutical ETF (NASDAQ:PPH – Get Free Report) reached a new 52-week high during trading on Monday. The company traded as high as $124.17 and last traded at $123.36, with a volume of 24,157 shares traded. The stock had previously closed at $122.65.

VanEck Pharmaceutical ETF Stock Up 0.4%

The firm has a market capitalization of $1.11 billion, a PE ratio of 29.81 and a beta of 0.43. The firm’s 50 day moving average price is $113.65 and its two-hundred day moving average price is $108.68.

VanEck Pharmaceutical ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, October 6th. Investors of record on Thursday, October 1st were paid a dividend of $0.36 per share. This is a negative change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248. The ex-dividend date of this dividend was Thursday, October 1st. This represents a $1.44 annualized dividend and a yield of 1.2%.

Hedge Funds Weigh In On VanEck Pharmaceutical ETF

A number of institutional investors have recently added to or reduced their stakes in PPH. Oppenheimer & Co. Inc. bought a new stake in shares of VanEck Pharmaceutical ETF in the third quarter worth $711,000. Fluent Financial LLC acquired a new stake in VanEck Pharmaceutical ETF during the second quarter worth about $4,264,000. Adamsbrown Wealth Consultants LLC lifted its holdings in shares of VanEck Pharmaceutical ETF by 3.6% in the 2nd quarter. Adamsbrown Wealth Consultants LLC now owns 154,114 shares of the company’s stock worth $16,852,000 after purchasing an additional 5,303 shares during the last quarter. Independent Financial Group LLC bought a new stake in VanEck Pharmaceutical ETF in the first quarter valued at $532,000. Finally, Avior Wealth Management LLC bought a new stake in VanEck Pharmaceutical ETF in the 3rd quarter valued at about $1,685,000.

VanEck Pharmaceutical ETF Company Profile

(Get Free Report)

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.

Read More

Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.